The search for CJC-1295 in Tāngi consistently ends with the same conclusion: research peptides are supplied via specialist online vendors, not high-street stores. The core insight for Tāngi researchers: sourcing CJC-1295 comes down completely to vendor quality evaluation, not geography — and the framework for evaluating that quality is identical for researchers everywhere. A properly operating CJC-1295 supplier's COA needs to show HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all batch-matched to your order. The sections below cover what Tāngi researchers need to know about sourcing, verifying, and handling CJC-1295 for legitimate research applications.
CJC-1295: What the Research Shows
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Tāngi researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
The first step for any Tāngi researcher sourcing CJC-1295 is locating suppliers that experienced researchers actively recommend — organic rankings are no guide to actual CJC-1295 quality. Mass spectrometry in the COA confirms that the main HPLC peak is actually CJC-1295 and not a structurally similar impurity — HPLC purity alone cannot verify molecular identity. For Tāngi researchers evaluating vendors with limited track records: a modest first purchase to test the product before committing to research quantities is standard practice in the community. Hold lyophilised CJC-1295 at minus 20 degrees Celsius until ready to use; reconstitute only the quantity required for your immediate research and return unused portion to the freezer.
Order CJC-1295 — ships to Tāngi
COA-verified · International tracking · Research grade
CJC-1295 is sold for research purposes only and is not approved for human use by the FDA or equivalent agencies worldwide — all information here is provided for educational purposes. Proper handling of CJC-1295 requires careful sterile procedure — swabbed septum with alcohol prep pad, new needle for each draw, clean preparation area — and consistent cold chain handling. Endotoxin testing in the CJC-1295 COA is not optional — gram-negative bacterial endotoxins can trigger severe inflammatory responses at very low concentrations, and no discount compensates for this missing data. Protocol documentation — keeping clear records of compound, timing, and method — is a sound practice for any CJC-1295 protocol that makes anomalous results interpretable.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
